title: Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
abstract: We have reported previously that s.c. immunization of rats with IL-4 transduced 9L gliosarcoma cells (9L-IL-4) induced a potent antitumor immunity against intracranial, parental 9L tumors. Subcutaneous implantation of 9L-IL-4 influenced the systemic humoral response, which was demonstrated by Th2-type isotype-switching and the induction of cellular immune responses, which played a critical role in the rejection of tumors. Serological analyses of recombinant cDNA expression libraries (SEREX), has recently emerged as a powerful method for serological identification of tumor-associated antigens (TAAs) and/or tumor rejection antigens (TRAs). Because IL-4 is known to activate B cells and to promote humoral responses, and inasmuch as induction of humoral responses by central nervous system tumors has been reported to be minimal, we investigated whether the induction of a potent humoral immune response against 9L TAAs or TRAs in rats immunized s.c. with 9L-IL4 could be demonstrated. Screening of 5 x 10(5) independent clones of 9L-expression cDNA library for the presence of reactive antibodies in the serum from a 91-IL-4 immunized rat led to the identification of three different TAAs. One 9L TAA (clone 29) was demonstrated to be calcyclin, a member of the S-100 family of calcium-binding proteins. The second 9L TAA (clone 37) was demonstrated to be the rat homologue of the J6B7 mouse immunomodulatory molecule. The third TAA (clones 158 and 171) was determined to be the rat homologue of the mouse Id-associated protein 1 (MIDA1), a DNA-binding, protein-associated protein. Northern blotting demonstrated that message for calcyclin was overexpressed in 9L cells. Message encoding MIDA1 was highly expressed in parental 9L cells and thymus and, to a lesser degree, in testis, suggesting that MIDA1 was comparable with the cancer/testis category of TAAs. Sera obtained from animals bearing 9L-IL-4 were found to have a higher a frequency and titer of antibodies to these antigens when compared with sera obtained from rats bearing sham-transduced 9L (9L-neo) cells. To determine whether immunization with these TAAs induced antitumor immunity, animals were immunized by intradermal injection with expression plasmids encoding calcyclin or MIDA1. Subsequent challenge of rats with parental 9L resulted in significant suppression of tumor growth in animals immunized with MIDA1, but not with calcyclin. These results indicate that MIDA1 is an effective 9L TRA and will be useful for the investigation of specific antitumor immunity in this glioma model. Furthermore, these results suggest that this approach, termed "cytokine-assisted SEREX (CAS)," may serve as an effective strategy for identification of TRAs for in animal-glioma models of cytokine gene therapy, and potentially in humans undergoing cytokine gene therapy protocols as well.
authors: Brain Tumor Center, University of Pittsburgh Cancer Institute, Department of Neurological Surgery, University of Pittsburgh School of Medicine, PA 15213, USA. okadah@msx.upmc.edu
authors: H
authors: H
authors: Okada
authors: J
authors: J
authors: Attanucci
authors: K M
authors: KM
authors: Giezeman-Smits
authors: C
authors: C
authors: Brissette-Storkus
authors: W K
authors: WK
authors: Fellows
authors: A
authors: A
authors: Gambotto
authors: L F
authors: LF
authors: Pollack
authors: K
authors: K
authors: Pogue-Geile
authors: M T
authors: MT
authors: Lotze
authors: M E
authors: ME
authors: Bozik
authors: W H
authors: WH
authors: Chambers
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000276:immunology; D000951:Antigens, Neoplasm / Q000097:blood / Q000276:immunology* / Q000302:isolation & purification; D001483:Base Sequence; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology*; D018797:Cell Cycle Proteins; D002455:Cell Division / Q000276:immunology; D018076:DNA, Complementary / Q000008:administration & dosage / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics / Q000276:immunology; D018316:Gliosarcoma / Q000276:immunology* / Q000473:pathology; D007132:Immunoglobulin Isotypes / Q000276:immunology; D007134:Immunoglobulin Switch Region / Q000276:immunology; D015847:Interleukin-4 / Q000235:genetics / Q000276:immunology; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D051381:Rats; D011916:Rats, Inbred F344; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins / Q000235:genetics / Q000276:immunology; D012680:Sensitivity and Specificity; D012698:Serologic Tests / Q000379:methods*; D018418:Th2 Cells / Q000276:immunology; D014407:Tumor Cells, Cultured; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018797:Cell Cycle Proteins; D018076:DNA, Complementary; D004268:DNA-Binding Proteins; D007132:Immunoglobulin Isotypes; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins; C489134:S100a6 protein, mouse; C489132:S100a6 protein, rat; D019444:Vaccines, DNA; C096145:Zrf2 protein, mouse; D015847:Interleukin-4